Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study
Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)
Objective: To explore the potential for an immunologically based intervention to slow evolution of symptoms in persons with prodromal or Stage 2b (Simuni et al.…Treatment Patterns in Essential Tremor: Real-World Evidence from Germany
Objective: To investigate the treatment patterns (TP), healthcare resource utilization (HCRU), and costs of essential tremor (ET) in a real-world setting in Germany using insurance…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model
Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity
Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 34
- Next Page »